Intismeran autogene (mRNA-4157)

Overview

An individualized neoantigen cancer therapy, co-developed with Merck, that is custom-manufactured for each patient's tumor mutations and given with KEYTRUDA to train the immune system against the cancer. It is Moderna's highest-value pipeline asset.

Investigational. Phase 2b in resected high-risk melanoma showed a ~49% reduction in recurrence-or-death risk versus KEYTRUDA alone, sustained at five years. Phase 3 INTerpath-001 (adjuvant melanoma) is fully enrolled and Phase 3 lung-cancer trials are enrolling, across nine Phase 2/3 oncology studies.

Key Specs